Navigation Links
Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome
Date:4/4/2008

Japanese and Other Ethnic Minorities at Increased Risk

BALTIMORE, April 4, 2008 /PRNewswire/ -- Newly published data by Dr. J. Barthelow Classen in The Open Endocrinology Journal shows a 50% reduction of type 2 diabetes occurred in Japanese children following the discontinuation of a single vaccine, a vaccine to prevent tuberculosis. This decline occurred at a time when there is a global epidemic of type 2 diabetes and metabolic syndrome, which includes obesity, altered blood cholesterol levels, high blood pressure, and increased blood glucose resulting from insulin resistance.

Classen proposes a new explanation for the epidemic of both insulin dependent diabetes (type 1 diabetes), which has previously been shown to be caused by vaccines and non insulin dependent diabetes (type 2 diabetes). Upon receipt of vaccines or other strong immune stimulants some individuals develop a hyperactive immune system leading to autoimmune destruction of insulin secreting cells. Other individuals produce increased cortisol, an immune suppressing hormone, to suppress the vaccine induced inflammation. The increased cortisol leads to type 2 diabetes and metabolic syndrome. Japanese children have increased cortisol secretion following immunization compared to White children and this explains why Japanese have a relative high rate of type 2 diabetes but low rate of insulin dependent diabetes compared to Whites. The lower cortisol response attributed to type 1 diabetes and the higher cortisol response attributed to type 2 diabetes explains why type 1 diabetics are generally leaner than type 2 diabetics since elevated cortisol causes weight gain.

"The current data shows that vaccines are much more dangerous than the public is lead to believe and adequate testing has never been performed even in healthy subjects to indicate that there is an overall improvement in health from immunization. The current practice of vaccinating diabetics as well as their close
'/>"/>

SOURCE Classen Immunotherapies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
2. Clinical trial will test new HIV/AIDS vaccine
3. Researchers Successfully Test Ebola Vaccines
4. MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk
5. HIV Vaccine Funding: Enough is Enough, Says AHF in Baltimore Sun
6. NIAID to convene HIV Vaccine Summit
7. Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
8. UNC, Harvard develop inhaled TB vaccine
9. U.S. Health Officials Back Off Preference for New MMRV Vaccine
10. Inhaled tuberculosis vaccine more effective than traditional shot
11. HPV vaccine reduces abnormal pap test results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3ASTRO Gildas Club Chicago join to promote cancer survivorship 59515 1Biomedical Research Centre searches for immunological biomarkers 59513 1Biomedical Research Centre searches for immunological biomarkers 59513 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 1KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 4